Kindred Biosciences, a clinical-stage biotech developing pet therapeutics, filed on Friday with the SEC to raise up to $58 million in an initial public offering. The Burlingame, CA-based company, which was founded in 2012, plans to list on the NASDAQ under the symbol KIN. Kindred Biosciences initially filed confidentially on October 2, 2013. BMO Capital Markets and Guggenheim Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
